Enanta Pharmaceuticals, Inc. announced that Marc E. Goldberg and David Poorvin, Ph.D. have submitted their resignations as directors, effective as of February 5, 2014, the day before their terms would otherwise expire at the 2014 annual meeting of stockholders. These resignations are not the result of any disagreement with Enanta on any matter relating to its operations, policies or practices. In addition to his service on Enanta's Board of Directors, Mr. Goldberg served as a member of the Board's Audit Committee and its Nominating and Corporate Governance Committee and was Chair of its Compensation Committee.

Dr. Poorvin also served as a member of the Board's Audit Committee and its Nominating and Corporate Governance Committee.